Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
Posted: Thu Jan 28, 2016 12:55 pm
Revised RECIST Guideline Version
1.1: What Oncologists Want to
Know and What Radiologists Need
to Know
Terms to understand when radiololigist and doctors describe your treatment progress or lack there of--
TABLE 1: Evaluation of Target and Nontarget Lesions by Response Evaluation Criteria in Solid Tumors
(RECIST), Version 1.0
Response Assessment RECIST Guideline, Version 1.0
Evaluation of target lesions-
CR Disappearance of all target lesions
PR ≥ 30% decrease in the sum of the longest diameters of target lesions compared with baseline
PD ≥ 20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
diameter recorded or the appearance of one or more new lesions
SD Neither PR or PD
Evaluation of nontarget lesions
CR Disappearance of all nontarget lesions and normalization of tumor marker level
Incomplete response, SD Persistence of one or more nontarget lesions and/or the maintenance of tumor marker level above the normal limits
PD Appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions
Note—CR = complete response, PR = partial response, PD = progressive disease, SD = stable disease.
http://www.ajronline.org/doi/pdf/10.2214/AJR.09.4110
1.1: What Oncologists Want to
Know and What Radiologists Need
to Know
Terms to understand when radiololigist and doctors describe your treatment progress or lack there of--

TABLE 1: Evaluation of Target and Nontarget Lesions by Response Evaluation Criteria in Solid Tumors
(RECIST), Version 1.0
Response Assessment RECIST Guideline, Version 1.0
Evaluation of target lesions-
CR Disappearance of all target lesions
PR ≥ 30% decrease in the sum of the longest diameters of target lesions compared with baseline
PD ≥ 20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
diameter recorded or the appearance of one or more new lesions
SD Neither PR or PD
Evaluation of nontarget lesions
CR Disappearance of all nontarget lesions and normalization of tumor marker level
Incomplete response, SD Persistence of one or more nontarget lesions and/or the maintenance of tumor marker level above the normal limits
PD Appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions
Note—CR = complete response, PR = partial response, PD = progressive disease, SD = stable disease.
http://www.ajronline.org/doi/pdf/10.2214/AJR.09.4110